News & Updates

Dietary niacin intake may benefit individuals with nonalcoholic fatty liver disease (NAFLD), with a study suggesting that a higher intake lowers the risk of mortality.

In the EMERALD-1 trial, durvalumab plus bevacizumab (D+B) combined with transarterial chemoembolization (TACE) improved progression-free survival (PFS) in individuals with unresectable hepatocellular carcinoma (HCC) eligible for embolization.

Treatment with larsucosterol is safe and well tolerated in patients with alcohol-associated hepatitis (AH), as shown in a recent study.

Noncontrast-enhanced magnetic resonance imaging (NCEMRI) demonstrates superiority over ultrasonography (US) for the surveillance of hepatocellular carcinoma (HCC) in at-risk populations, although this strategy is more expensive than US, according to a Singapore study.

Patients with liver disease develop antibodies and T-cell responses following three shots of COVID-19 vaccines, while those who have been infected with SARS-CoV-2 develop mild symptoms only, reports a recent study.

A novel risk score, PAGED-B, may be used to predict hepatocellular carcinoma (HCC) development at the time of transition into hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB), suggests a study.